Brief: Alphamab Oncology Says Strategic Collaboration With Sanofi On Kn026 In Her2+ Breast Cancer
09/06/2020 02:43
June 9 (Reuters) - Alphamab Oncology 9966.HK :
* STRATEGIC COLLABORATION WITH SANOFI ON KN026 IN HER2+
BREAST
CANCER
* UNITS OF CO, SANOFI ENTERED EXCLUSIVE OPTION DEAL FOR
STUDIES ON
KN026 WITH TAXOTERE IN PATIENTS WITH HER2-POSITIVE BREAST CANCER
Source text https://bit.ly/2UoJgpo
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)